# Adaptive Biotechnologies

**Canonical:** https://apis.io/providers/adaptive-biotechnologies/  
**Website:** https://www.adaptivebiotech.com/  
**APIs profiled:** 0

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a Seattle, Washington immune-medicine company that reads and translates the adaptive immune system at scale. Founded in 2009 by brothers Chad Robins and Harlan Robins as Adaptive TCR Corporation, it built an immunosequencing platform that amplifies and sequences rearranged T-cell and B-cell receptor genes, then applies computational models to turn that receptor repertoire into clinical and research data. Its lead commercial product is clonoSEQ, an FDA-cleared next-generation sequencing assay for measurable residual disease (MRD) in multiple myeloma, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma and diffuse large B-cell lymphoma, run out of its CLIA-certified, CAP-accredited Seattle laboratory. It also sells immunoSEQ research assays with the cloud-based immunoSEQ Analyzer and the immuneACCESS public data repository, and MRD biopharma services to drug developers. Adaptive is a diagnostics and services company, not a software vendor: it publishes no developer portal, no public API reference and no machine-readable specification. Its integration surface is clinician-facing and delivered bilaterally — clonoSEQ orders and results flow through Epic (including Epic Aura), Flatiron Health's OncoEMR via Molecular Profiling Integration, and Carequality/health information exchanges, arranged through its EMR integration specialists rather than through self-serve documentation.

## Kin Score — 17.4 / 100 (emerging)

Scored 2026-09-07 under rubric 0.20.0.

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 18.2 |
| Contract Governance | 18.2 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 7.1 |
| Commercial Clarity | 35.5 |
| Access Clarity | 35.5 |

Regulatory layer — **Health**: 30.0 (matched via tags).

## Agent readiness — 5.4 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | documented |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | yes |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Security (1)

- **Adaptive Biotechnologies Domain Security** — TLSv1.3 · HSTS · DMARC

## Plans (1)

- **Adaptive Biotechnologies Plans Pricing**

## Tags

Company, Biotechnology, Life Sciences, Genomics, Immunology, Clinical Diagnostics, Oncology, Health Care, Laboratory, Precision Medicine, Data

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/adaptive-biotechnologies/). Scores are computed from the provider's own public artifacts under a published rubric.